Soligenix, Inc. (NASDAQ:SNGX) Short Interest Up 624.7% in April

Soligenix, Inc. (NASDAQ:SNGX) was the target of a significant growth in short interest in April. As of April 15th, there was short interest totalling 839,200 shares, a growth of 624.7% from the March 31st total of 115,800 shares. Approximately 8.0% of the shares of the stock are sold short. Based on an average daily volume of 2,560,000 shares, the days-to-cover ratio is currently 0.3 days.

Soligenix Price Performance

Shares of SNGX traded up $0.04 during trading hours on Thursday, reaching $0.43. 681,062 shares of the stock traded hands, compared to its average volume of 2,965,656. The company has a market cap of $4.43 million, a P/E ratio of -0.47 and a beta of 1.81. The company has a current ratio of 1.55, a quick ratio of 1.52 and a debt-to-equity ratio of 0.40. The company’s 50-day moving average price is $0.61 and its two-hundred day moving average price is $0.61. Soligenix has a 52-week low of $0.37 and a 52-week high of $4.20.

Soligenix (NASDAQ:SNGX) last posted its quarterly earnings results on Friday, March 15th. The biopharmaceutical company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.03. The business had revenue of $0.25 million for the quarter, compared to analysts’ expectations of $0.20 million. Soligenix had a negative return on equity of 251.07% and a negative net margin of 731.94%. On average, analysts anticipate that Soligenix will post 0.81 earnings per share for the current year.

Soligenix Company Profile

Soligenix, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease.